Heart failure represents a widespread and intricate clinical condition arising from structural or functional heart disorders. This impairment disrupts the heart’s ability to adequately fill with or eject blood, hindering systemic circulation from meeting the body’s metabolic demands. Numerous underlying diseases can precipitate heart failure, with the majority of patients exhibiting symptoms stemming from compromised left ventricular myocardial function. Common patient presentations include dyspnea, fatigue, reduced exercise capacity, and fluid retention, clinically manifested as pulmonary and peripheral edema.
Heart failure resulting from left ventricular dysfunction is categorized based on left ventricular ejection fraction (LVEF) into two primary classifications: heart failure with reduced ejection fraction (HFrEF), defined as an LVEF of 40% or less, and heart failure with preserved ejection fraction (HFpEF), characterized by an LVEF exceeding 40%.
Nursing Diagnoses Related to Congestive Heart Failure
Nursing care for patients with congestive heart failure often addresses several key diagnoses, including:
- Decreased cardiac output
- Activity intolerance
- Excess fluid volume
- Risk for impaired skin integrity
- Ineffective tissue perfusion
- Ineffective breathing pattern
- Impaired gas exchange
- Fatigue
- Anxiety
Common Causes of Congestive Heart Failure
Congestive heart failure can stem from a diverse array of disorders affecting various cardiac structures, including the pericardium, myocardium, endocardium, heart valves, vasculature, and metabolic processes. Systolic dysfunction (HFrEF) is most frequently attributed to idiopathic dilated cardiomyopathy (DCM), coronary heart disease (ischemic), hypertension, and valvular disease. Diastolic dysfunction (HFpEF) shares similar etiological factors, with the addition of hypertrophic obstructive cardiomyopathy and restrictive cardiomyopathy as significant contributors.
Risk Factors for Developing Congestive Heart Failure
Several risk factors are strongly associated with an increased likelihood of developing congestive heart failure:
- Coronary artery disease
- Myocardial infarction (heart attack)
- Hypertension (high blood pressure)
- Diabetes mellitus
- Obesity
- Smoking
- Alcohol use disorder
- Atrial fibrillation
- Thyroid diseases
- Congenital heart disease
- Aortic stenosis
Assessment and Clinical Manifestations of Congestive Heart Failure
Symptoms of congestive heart failure arise from both fluid overload and reduced cardiac output. Fluid accumulation leads to dyspnea (shortness of breath), orthopnea (difficulty breathing while lying down), edema (swelling), hepatic congestion causing abdominal pain, and ascites (abdominal distention). Reduced cardiac output manifests as fatigue and weakness, particularly during physical exertion.
Acute or subacute presentations (over days to weeks) are marked by shortness of breath at rest or with exertion, orthopnea, paroxysmal nocturnal dyspnea (sudden nighttime breathlessness), and right upper quadrant discomfort due to acute hepatic congestion associated with right heart failure. Palpitations, sometimes accompanied by lightheadedness, may occur if the patient develops atrial or ventricular tachyarrhythmias.
Chronic presentations (over months) may present with fatigue, anorexia, abdominal distension, and peripheral edema as more prominent features than dyspnea. Anorexia in chronic heart failure is multifactorial, resulting from poor perfusion of the splanchnic circulation, bowel edema, and nausea induced by hepatic congestion.
Characteristic clinical findings in congestive heart failure include:
- Pulsus alternans: An alternating strong and weak peripheral pulse, despite a regular heart rhythm, indicating left ventricular systolic dysfunction.
- Apical impulse: Displacement of the apical impulse laterally beyond the midclavicular line, often signifying left ventricular enlargement.
- S3 gallop: A low-frequency heart sound in early diastole, a sensitive indicator of ventricular dysfunction.
- Peripheral edema: Swelling in the extremities due to fluid retention.
- Pulmonary rales (crackles): Abnormal lung sounds indicating fluid in the air spaces.
New York Heart Association (NYHA) Functional Classification
The NYHA classification system categorizes heart failure severity based on symptom limitations:
- Class I: Symptoms occur only with more than ordinary physical activity.
- Class II: Symptoms occur with ordinary physical activity.
- Class III: Symptoms occur with minimal physical activity.
- Class IV: Symptoms are present even at rest.
Diagnostic Evaluation for Congestive Heart Failure
Evaluation of suspected congestive heart failure involves several diagnostic tests:
- Electrocardiogram (ECG): Used to detect evidence of prior myocardial infarction, acute ischemia, or rhythm abnormalities like atrial fibrillation.
- Chest X-ray: May reveal cardiomegaly (enlarged heart), pulmonary vascular congestion (cephalization of pulmonary vessels), Kerley B-lines (indicators of interstitial edema), and pleural effusions.
- Blood Tests: Include cardiac troponin (to rule out acute myocardial infarction), complete blood count, serum electrolytes, blood urea nitrogen, creatinine, liver function tests, and brain natriuretic peptide (BNP). BNP or NT-proBNP levels are particularly valuable in diagnosing heart failure, often providing more diagnostic insight than other initial tests. Elevated BNP levels strongly suggest heart failure.
- Transthoracic Echocardiogram: Essential for assessing ventricular function, ejection fraction, valve function, and hemodynamics. It helps differentiate between HFrEF and HFpEF and identify structural heart abnormalities.
Medical Management and Congestive Heart Failure Care Plan
Pharmacological management is the cornerstone of medical treatment for congestive heart failure. Medications are selected based on the patient’s functional class, severity of symptoms, and ejection fraction. Common medication classes include:
- Diuretics: To reduce fluid overload and alleviate symptoms like edema and dyspnea.
- Beta-blockers: To improve survival and reduce hospitalization, particularly in HFrEF.
- Angiotensin-converting enzyme inhibitors (ACEIs) or Angiotensin receptor blockers (ARBs): To improve survival, reduce hospitalization, and manage blood pressure in HFrEF.
- Angiotensin receptor neprilysin inhibitor (ARNI): Such as sacubitril/valsartan, ARNI therapy has shown to be more effective than ACEIs in reducing mortality and hospitalization in HFrEF. ARNI should not be administered within 36 hours of an ACE inhibitor dose.
- Hydralazine and Nitrate combination: Particularly beneficial in African-American patients with persistent NYHA class III to IV HFrEF despite optimal medical therapy.
- Digoxin: To control heart rate in atrial fibrillation and improve symptoms in some patients.
- Aldosterone antagonists (Mineralocorticoid Receptor Antagonists – MRAs): Such as spironolactone or eplerenone, to improve survival in HFrEF.
Combination therapy using several of these agents is often necessary to optimize outcomes and reduce hospitalizations.
Device Therapy:
- Implantable cardioverter-defibrillator (ICD): Used for primary or secondary prevention of sudden cardiac death in patients at risk for life-threatening arrhythmias.
- Cardiac resynchronization therapy (CRT): Biventricular pacing can improve symptoms and survival in select patients with HFrEF, sinus rhythm, and prolonged QRS duration, indicating conduction delays. Often combined with an ICD (CRT-D).
- Ventricular assist device (VAD): May be used as a bridge to heart transplantation or as destination therapy for patients with severe heart failure who are not candidates for transplant.
- Cardiac transplantation: Reserved for patients with end-stage heart failure despite maximal medical and device therapy.
Nursing Management in the Congestive Heart Failure Care Plan
Nursing care is integral to the comprehensive management of congestive heart failure. Key components of a nursing care plan include:
- Relieving fluid overload symptoms: Administering diuretics as prescribed, monitoring fluid balance, and positioning patients to ease breathing.
- Relieving symptoms of anxiety and fatigue: Providing emotional support, promoting rest, and managing symptoms that contribute to fatigue.
- Promoting physical activity: Encouraging regular, moderate exercise within the patient’s tolerance, and providing guidance on safe activity levels.
- Increasing medication compliance: Educating patients about their medications, potential side effects, and the importance of adherence.
- Decreasing adverse effects of treatment: Monitoring for and managing side effects of medications, such as electrolyte imbalances or hypotension.
- Teaching patients about dietary restrictions: Educating on sodium restriction (typically 2-3 grams per day) and fluid restriction (usually 2 liters per day) to manage fluid overload.
- Teaching patient about self-monitoring of symptoms: Instructing patients on how to recognize worsening symptoms, such as increased shortness of breath, edema, or weight gain, and when to seek medical attention.
- Teaching patients about daily weight monitoring: Educating patients on the importance of daily weight measurement to detect fluid retention early.
When to Seek Prompt Medical Attention for Congestive Heart Failure
Patients should be educated to seek immediate medical attention if they experience any of the following:
- Worsening symptoms of fluid overload (rapid weight gain, increased edema, worsening shortness of breath).
- Worsening hypoxia (increased shortness of breath, especially at rest, or bluish lips or nailbeds).
- Uncontrolled tachycardia (rapid heart rate) regardless of rhythm.
- Change in cardiac rhythm (palpitations, irregular heartbeats).
- Change in mental status (confusion, dizziness, lightheadedness).
- Decreased urinary output despite diuretic therapy.
Monitoring Congestive Heart Failure
Regular monitoring is crucial for patients with congestive heart failure:
- Vital signs: Frequent monitoring of blood pressure, heart rate, respiratory rate, temperature, and oxygen saturation.
- Telemetry monitoring: Continuous heart rate and rhythm monitoring may be necessary, especially during acute exacerbations or hospitalization.
- Symptom assessment: Regular assessment for changes in symptoms, fluid status, and overall clinical condition.
- Daily weight monitoring: Essential for detecting fluid retention and guiding diuretic therapy.
Coordination of Care for Congestive Heart Failure
Effective management of congestive heart failure requires a multidisciplinary approach involving:
- Primary care physician
- Cardiologist
- Emergency department physician
- Radiologist
- Cardiac nurses
- Internist
- Cardiac surgeons
- Pharmacists
- Dietitians
- Rehabilitation specialists
Treating the underlying cause of heart failure is paramount. Healthcare professionals must adhere to current heart failure management guidelines. Patient education on medication adherence and lifestyle modifications is critical for improving outcomes and quality of life. Lack of appropriate management can lead to high morbidity and mortality.
Health Education and Health Promotion for Congestive Heart Failure
Patient education is a cornerstone of congestive heart failure care, aimed at improving clinical outcomes and reducing hospital readmissions. Key educational components include:
- Self-monitoring of symptoms at home and understanding when to seek help.
- Medication management and the importance of compliance.
- Daily weight monitoring and its significance.
- Dietary sodium restriction (2-3 g/day).
- Daily fluid restriction (2 L/day).
- Lifestyle modifications, including smoking cessation, alcohol moderation, and weight management.
- Management of co-existing conditions like diabetes, hypertension, and sleep apnea. Patients with sleep apnea and heart failure should be encouraged to use CPAP therapy.
Discharge Planning for Congestive Heart Failure
Discharge planning is essential to ensure a smooth transition from hospital to home and to prevent readmissions. Discharge planning includes:
- Comprehensive patient education on all aspects of their care plan, including medications, diet, activity, and symptom recognition.
- Ensuring follow-up appointments with their physician or heart failure clinic.
- Nurse-driven education at discharge has been shown to improve therapy adherence and patient outcomes.
- Connecting patients with resources and support systems, such as heart failure support groups or home healthcare services if needed.
Review Questions (Self-Assessment)
[Review questions from original article would be placed here if applicable]
Figure
Congestive Heart Failure, Radiograph. Chest radiographs are crucial in evaluating pulmonary congestion or edema in acute decompensated heart failure, aiding in diagnosis and monitoring. Contributed by S Bhimji, MD
References
[References from original article are listed here, maintaining original citation format and links]
1.Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW., ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 03;145(18):e895-e1032. [PubMed: 35363499]
2.Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016 Jun;13(6):368-78. [PMC free article: PMC4868779] [PubMed: 26935038]
3.CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 Jun 04;316(23):1429-35. [PubMed: 2883575]
4.Lind L, Ingelsson M, Sundstrom J, Ärnlöv J. Impact of risk factors for major cardiovascular diseases: a comparison of life-time observational and Mendelian randomisation findings. Open Heart. 2021 Sep;8(2) [PMC free article: PMC8438838] [PubMed: 34518286]
5.Noubiap JJ, Agbor VN, Bigna JJ, Kaze AD, Nyaga UF, Mayosi BM. Prevalence and progression of rheumatic heart disease: a global systematic review and meta-analysis of population-based echocardiographic studies. Sci Rep. 2019 Nov 19;9(1):17022. [PMC free article: PMC6863880] [PubMed: 31745178]
6.Kim KH, Pereira NL. Genetics of Cardiomyopathy: Clinical and Mechanistic Implications for Heart Failure. Korean Circ J. 2021 Oct;51(10):797-836. [PMC free article: PMC8484993] [PubMed: 34327881]
7.Rezkalla SH, Kloner RA. Viral myocarditis: 1917-2020: From the Influenza A to the COVID-19 pandemics. Trends Cardiovasc Med. 2021 Apr;31(3):163-169. [PMC free article: PMC7965406] [PubMed: 33383171]
8.Muchtar E, Blauwet LA, Gertz MA. Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circ Res. 2017 Sep 15;121(7):819-837. [PubMed: 28912185]
9.Shams P, Ahmed I. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Cardiac Amyloidosis. [PubMed: 35593829]
10.Brown KN, Pendela VS, Ahmed I, Diaz RR. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 30, 2023. Restrictive Cardiomyopathy. [PubMed: 30725919]
11.Matta AG, Carrié D. Epidemiology, Pathophysiology, Diagnosis, and Principles of Management of Takotsubo Cardiomyopathy: A Review. Med Sci Monit. 2023 Mar 06;29:e939020. [PMC free article: PMC9999670] [PubMed: 36872594]
12.Bairashevskaia AV, Belogubova SY, Kondratiuk MR, Rudnova DS, Sologova SS, Tereshkina OI, Avakyan EI. Update of Takotsubo cardiomyopathy: Present experience and outlook for the future. Int J Cardiol Heart Vasc. 2022 Apr;39:100990. [PMC free article: PMC8913320] [PubMed: 35281752]
13.Ahmad SA, Brito D, Khalid N, Ibrahim MA. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): May 22, 2023. Takotsubo Cardiomyopathy. [PubMed: 28613549]
14.DeFilippis EM, Beale A, Martyn T, Agarwal A, Elkayam U, Lam CSP, Hsich E. Heart Failure Subtypes and Cardiomyopathies in Women. Circ Res. 2022 Feb 18;130(4):436-454. [PMC free article: PMC10361647] [PubMed: 35175847]
15.Wong CM, Hawkins NM, Jhund PS, MacDonald MR, Solomon SD, Granger CB, Yusuf S, Pfeffer MA, Swedberg K, Petrie MC, McMurray JJ. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). J Am Coll Cardiol. 2013 Nov 12;62(20):1845-54. [PubMed: 23850914]
16.Sciomer S, Moscucci F, Salvioni E, Marchese G, Bussotti M, Corrà U, Piepoli MF. Role of gender, age and BMI in prognosis of heart failure. Eur J Prev Cardiol. 2020 Dec;27(2_suppl):46-51. [PMC free article: PMC7691623] [PubMed: 33238736]
17.Volpe M, Gallo G. Obesity and cardiovascular disease: An executive document on pathophysiological and clinical links promoted by the Italian Society of Cardiovascular Prevention (SIPREC). Front Cardiovasc Med. 2023;10:1136340. [PMC free article: PMC10040794] [PubMed: 36993998]
18.Kim DY, Kim SH, Ryu KH. Tachycardia induced Cardiomyopathy. Korean Circ J. 2019 Sep;49(9):808-817. [PMC free article: PMC6713829] [PubMed: 31456374]
19.Anakwue RC, Onwubere BJ, Anisiuba BC, Ikeh VO, Mbah A, Ike SO. Congestive heart failure in subjects with thyrotoxicosis in a black community. Vasc Health Risk Manag. 2010 Aug 09;6:473-7. [PMC free article: PMC2922308] [PubMed: 20730063]
20.Schoenenberger AW, Schoenenberger-Berzins R, der Maur CA, Suter PM, Vergopoulos A, Erne P. Thiamine supplementation in symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled, cross-over pilot study. Clin Res Cardiol. 2012 Mar;101(3):159-64. [PubMed: 22057652]
21.DiNicolantonio JJ, Liu J, O’Keefe JH. Thiamine and Cardiovascular Disease: A Literature Review. Prog Cardiovasc Dis. 2018 May-Jun;61(1):27-32. [PubMed: 29360523]
22.Reddy YNV, Melenovsky V, Redfield MM, Nishimura RA, Borlaug BA. High-Output Heart Failure: A 15-Year Experience. J Am Coll Cardiol. 2016 Aug 02;68(5):473-482. [PubMed: 27470455]
23.Chayanupatkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: review of pathophysiology and treatment. Hepatol Int. 2014 Jul;8(3):308-15. [PMC free article: PMC4160726] [PubMed: 25221635]
24.Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW., American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020 Mar 03;141(9):e139-e596. [PubMed: 31992061]
25.Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993 Oct;22(4 Suppl A):6A-13A. [PubMed: 8376698]
26.Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017 Mar 07;135(10):e146-e603. [PMC free article: PMC5408160] [PubMed: 28122885]
27.Yusuf S, Joseph P, Rangarajan S, Islam S, Mente A, Hystad P, Brauer M, Kutty VR, Gupta R, Wielgosz A, AlHabib KF, Dans A, Lopez-Jaramillo P, Avezum A, Lanas F, Oguz A, Kruger IM, Diaz R, Yusoff K, Mony P, Chifamba J, Yeates K, Kelishadi R, Yusufali A, Khatib R, Rahman O, Zatonska K, Iqbal R, Wei L, Bo H, Rosengren A, Kaur M, Mohan V, Lear SA, Teo KK, Leong D, O’Donnell M, McKee M, Dagenais G. Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lancet. 2020 Mar 07;395(10226):795-808. [PMC free article: PMC8006904] [PubMed: 31492503]
28.Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet. 2006 Jan 28;367(9507):356-67. [PubMed: 16443044]
29.Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol. 2012 Sep-Oct;21(5):365-71. [PubMed: 22227365]
30.Ait Mou Y, Bollensdorff C, Cazorla O, Magdi Y, de Tombe PP. Exploring cardiac biophysical properties. Glob Cardiol Sci Pract. 2015;2015:10. [PMC free article: PMC4448074] [PubMed: 26779498]
31.Abassi Z, Khoury EE, Karram T, Aronson D. Edema formation in congestive heart failure and the underlying mechanisms. Front Cardiovasc Med. 2022;9:933215. [PMC free article: PMC9553007] [PubMed: 36237903]
32.Prausmüller S, Arfsten H, Spinka G, Freitag C, Bartko PE, Goliasch G, Strunk G, Pavo N, Hülsmann M. Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF. J Am Heart Assoc. 2020 Jun 02;9(11):e015071. [PMC free article: PMC7428996] [PubMed: 32427034]
33.Docherty KF, Vaduganathan M, Solomon SD, McMurray JJV. Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. JACC Heart Fail. 2020 Oct;8(10):800-810. [PMC free article: PMC8837825] [PubMed: 33004114]
34.Obokata M, Reddy YNV, Borlaug BA. Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: Understanding Mechanisms by Using Noninvasive Methods. JACC Cardiovasc Imaging. 2020 Jan;13(1 Pt 2):245-257. [PMC free article: PMC6899218] [PubMed: 31202759]
35.Kao DP, Lewsey JD, Anand IS, Massie BM, Zile MR, Carson PE, McKelvie RS, Komajda M, McMurray JJ, Lindenfeld J. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015 Sep;17(9):925-35. [PMC free article: PMC4654630] [PubMed: 26250359]
36.Harjola VP, Mullens W, Banaszewski M, Bauersachs J, Brunner-La Rocca HP, Chioncel O, Collins SP, Doehner W, Filippatos GS, Flammer AJ, Fuhrmann V, Lainscak M, Lassus J, Legrand M, Masip J, Mueller C, Papp Z, Parissis J, Platz E, Rudiger A, Ruschitzka F, Schäfer A, Seferovic PM, Skouri H, Yilmaz MB, Mebazaa A. Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017 Jul;19(7):821-836. [PMC free article: PMC5734941] [PubMed: 28560717]
37.King M, Kingery J, Casey B. Diagnosis and evaluation of heart failure. Am Fam Physician. 2012 Jun 15;85(12):1161-8. [PubMed: 22962896]
38.Ali AS, Rybicki BA, Alam M, Wulbrecht N, Richer-Cornish K, Khaja F, Sabbah HN, Goldstein S. Clinical predictors of heart failure in patients with first acute myocardial infarction. Am Heart J. 1999 Dec;138(6 Pt 1):1133-9. [PubMed: 10577445]
39.Klein L, O’Connor CM, Leimberger JD, Gattis-Stough W, Piña IL, Felker GM, Adams KF, Califf RM, Gheorghiade M., OPTIME-CHF Investigators. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation. 2005 May 17;111(19):2454-60. [PubMed: 15867182]
40.Kelder JC, Cramer MJ, van Wijngaarden J, van Tooren R, Mosterd A, Moons KG, Lammers JW, Cowie MR, Grobbee DE, Hoes AW. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011 Dec 20;124(25):2865-73. [PubMed: 22104551]
41.Rørth R, Jhund PS, Yilmaz MB, Kristensen SL, Welsh P, Desai AS, Køber L, Prescott MF, Rouleau JL, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Circ Heart Fail. 2020 Feb;13(2):e006541. [PubMed: 32065760]
42.Hacker M, Hoyer X, Kupzyk S, La Fougere C, Kois J, Stempfle HU, Tiling R, Hahn K, Störk S. Clinical validation of the gated blood pool SPECT QBS processing software in congestive heart failure patients: correlation with MUGA, first-pass RNV and 2D-echocardiography. Int J Cardiovasc Imaging. 2006 Jun-Aug;22(3-4):407-16. [PubMed: 16328851]
43.Jain S, Londono FJ, Segers P, Gillebert TC, De Buyzere M, Chirinos JA. MRI Assessment of Diastolic and Systolic Intraventricular Pressure Gradients in Heart Failure. Curr Heart Fail Rep. 2016 Feb;13(1):37-46. [PubMed: 26780916]
44.Cahill TJ, Ashrafian H, Watkins H. Genetic cardiomyopathies causing heart failure. Circ Res. 2013 Aug 30;113(6):660-75. [PubMed: 23989711]
45.Peterson PN, Rumsfeld JS, Liang L, Albert NM, Hernandez AF, Peterson ED, Fonarow GC, Masoudi FA., American Heart Association Get With the Guidelines-Heart Failure Program. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program. Circ Cardiovasc Qual Outcomes. 2010 Jan;3(1):25-32. [PubMed: 20123668]
46.Lam CSP, Mulder H, Lopatin Y, Vazquez-Tanus JB, Siu D, Ezekowitz J, Pieske B, O’Connor CM, Roessig L, Patel MJ, Anstrom KJ, Hernandez AF, Armstrong PW., VICTORIA Study Group. Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. J Am Heart Assoc. 2021 Nov 16;10(22):e021094. [PMC free article: PMC8751950] [PubMed: 34743540]
47.Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, Ponikowski P, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O’Connor CM., VICTORIA Study Group. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2020 May 14;382(20):1883-1893. [PubMed: 32222134]
48.Lucas C, Johnson W, Hamilton MA, Fonarow GC, Woo MA, Flavell CM, Creaser JA, Stevenson LW. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000 Dec;140(6):840-7. [PubMed: 11099986]
49.Rider I, Sorensen M, Brady WJ, Gottlieb M, Benson S, Koyfman A, Long B. Disposition of acute decompensated heart failure from the emergency department: An evidence-based review. Am J Emerg Med. 2021 Dec;50:459-465. [PubMed: 34500232]
Disclosures: (Maintain original disclosures)
Disclosure: Ahmad Malik declares no relevant financial relationships with ineligible companies.
Disclosure: Lovely Chhabra declares no relevant financial relationships with ineligible companies.
Disclosure: Chaddie Doerr declares no relevant financial relationships with ineligible companies.
